Clinical Trial Update: A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC). [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating TQB2618 with Penpulimab and Anlotinib for first-line advanced hepatocellular carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Anlotinib hydrochloride capsules (anlotinib hydrochloride)
• Penpulimab
• TQB2618

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Advanced Hepatocellular Carcinoma | Phase 1 | Status: TERMINATED